Qiagen ( (QGEN) ) has shared an update.
QIAGEN N.V. announced a managerial transaction involving Toralf Haag, a member of the administrative or supervisory body. The transaction involved the release of 2,792 Restricted Stock Units, with an exercise price of $0 and a closing price of $38.40 on February 28, 2025. Following the release, 1,815 Common Shares were received upon net share settlement, with some shares withheld to cover expenses. Additionally, a grant of 5,990 Restricted Stock Units was made. This transaction is linked to the exercise of share option programs and reflects the company’s ongoing efforts to manage executive compensation and align managerial interests with shareholder value.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable customers to gain valuable insights from biological samples.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.